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ABSTRACT
This study analysed 89 episodes of catheter-rela-
ted bloodstream infection (CR-BSI) occurring dur-
ing one week in 107 hospitals from 21 European
countries (1.02 episodes ⁄ 1000 admissions).
Patients from European Union (EU) countries
had a higher incidence of CR-BSI than patients
from non-EU countries (1.55 vs. 0.33 ⁄ 1000 admis-
sions). Most (67%) catheters were non-tunneled
central venous catheters, were in the jugular vein
(44%), had been implanted for > 7 days (70%),
were made of polyurethane (61%) and were multi-
lumen (67%). In 36% of cases, catheters were
implanted by physicians other than anaesthetists
or surgeons, and 50%were inserted by junior staff.
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The objectives of this study (ESGNI-006) were
to define the clinical and epidemiological character-
istics of patients with catheter-related bloodstream
infections (CR-BSIs) in Europe. The study assessed
the situation in countries belonging to the Euro-
pean Union (EU) in comparison with that in
countries not belonging to the EU, and the charac-
teristics of the catheters involved were investigated.
ESGNI-006 was a cross-sectional survey of
CR-BSI performed over a 1-week period (22–26
October 2001). Patients with microbiologically
proven CR-BSI were recorded in each institution
during the study period. For each episode of
CR-BSI, a bedside evaluation and follow-up for a
maximum of 1 month were carried out. Data
collected from each patient with CR-BSI con-
cerned mostly the characteristics of the intraven-
ous catheter (IVC). Catheter colonisation, CR-BSI
and local signs of catheter infection were defined
according to published guidelines [1]. Continuous
variables were expressed as the mean and stand-
ard deviation (SD) and 95% confidence interval
(CI 95%). Student’s unpaired t-test was used to
compare continuous variables, and the chi-square
test was used to compare proportions.
Information was obtained from 107 hospitals of
different sizes from 21 countries (82 hospitals from
12 EU countries, and 25 from nine non-EU coun-
tries), serving an estimated population of 92 343 614
(Table 1). Overall, the total number of admissions in
these institutions during 2000 was 4 549 757. In
total, 89 patients presented with CR-BSI (16 from
non-EU countries, 73 from EU countries) during the
study period, with an estimated yearly incidence of
1.02 episodes ⁄ 1000 admissions (1.55 in EU coun-
tries, 0.39 in non-EU countries; p < 0.0001).
Of 105 different microorganisms isolated from
CR-BSI episodes, the seven most frequent were, in
decreasing order: coagulase-negative staphylo-
cocci (34%), Staphylococcus aureus (17%), Enterob-
acter spp. (9%), Candida spp. (9%), Klebsiella spp.
(6%), Pseudomonas spp. (6%) and Enterococcus spp.
(6%). Although coagulase-negative staphylococci
were the pathogens isolated most commonly in EU
countries, S. aureus was predominant in non-EU
countries (39% vs. 13%; p 0.01).
Only 31 patients with CR-BSI displayed local
signs of catheter infection. The characteristics of
the IVC in patients with CR-BSI are described in
Table 2. Most (67%) were non-tunneled central
venous catheters, the jugular vein was the most
frequent (44%) site of catheter insertion, and the
catheter material was mostly polyurethane (73%)
and was multi-lumen in 67% of cases. Povidone
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iodine was the type of skin disinfectant used most
commonly (71%). Total parenteral nutrition had
been given to 53.5% of patients with CR-BSI, and
was administered to 39% of patients through a
multi-lumen catheter.
Catheters were inserted by anaesthetists (56%),
surgeons (8%), radiologists (2%) and other spe-
cialists (34%). Junior doctors inserted 50% of the
catheters. The mean time from insertion to with-
drawal of catheters was 21 days (CI 95%:
11.3–30.3 days), with a median of 10 days. Of
patients with CR-BSI, 71% retained the IVC for
> 7 days. No differences were found between EU
and non-EU countries in this respect.
An assessment of the incidence of CR-BSI in
> 300 hospitals in the USA revealed an overall
incidence of 4.3–7.7 episodes ⁄ 1000 catheter days in
intensive care unit patients with short-term IVCs
[2]. Patients with other types of central venous
catheter, and with long-term tunneled catheters,
have an incidence of CR-BSI of 0.6–6 ⁄ 1000 catheter
days, as found in more limited studies [3,4]. In the
present study, an overall incidence of CR-BSI in
Europe was estimated according to the number of
admission days; such information is available more
easily than catheter days for broad-based studies,
and therefore can be useful as a baseline for
comparison in future studies assessing the impact
of possible interventions. The figure obtained was
close to one episode ⁄ 1000 hospital admissions, and
was significantly higher in EU countries. This
could reflect the admission of patients with more
complicated conditions who undergo more inva-
sive procedures for their management.
It was interesting to note that local signs of
infection were evident in < 50% of patients with
CR-BSI, as has been reported previously [1]. The
site of insertion is a recognised risk factor for
CR-BSI, and jugular vein catheters are more prone
to infection [5,6]. Accordingly, it is not surprising
that 44% of patients with CR-BSI included in the
present study had jugular vein catheters.
One potential point of intervention is the choice
of skin antiseptic. Despite the proven superiority
of aqueous chlorhexidine, povidone iodine was
the antiseptic used most widely (61%) for skin
preparation, as found in previous studies [7,8].
The expertise of the physician who inserts a
catheter has been shown to correlate with the rate
of complications and cost [9]. In the present study,
34% of catheters were not inserted by anaesthet-
ists or surgeons, and 50% were not inserted by
senior staff. Specially trained catheter teams for
inserting and maintaining catheters could reduce
the incidence of infection and costs [10].
In the present study, > 70% of patients with CR-
BSI had a catheter implanted for > 7 days. Dur-
ation of catheterisation is considered to be the
major risk factor for CR-BSI [11,12], and, although
some studies and meta-analyses have failed to
demonstrate the efficacy of periodic changes of
central venous catheter [13–16], early withdrawal
Table 2. Available data regarding intravenous catheters in
patients with catheter-related bloodstream infections
Total (89) EU (73) Non EU (16)
Time from insertion to removal of IVC
1–7 days 25 ⁄ 88 (28%) 17 ⁄ 72 (24%) 8 ⁄ 16 (50%)
8–30 days 54 ⁄ 88 (61%) 47 ⁄ 72 (65%) 7 ⁄ 16 (44%)
> 30 days 9 ⁄ 88 (10%) 8 ⁄ 72 (11%) 1 ⁄ 16 (6%)
Type of catheter
Non-tunneled CVC 60 ⁄ 89 (67%) 52 ⁄ 73 (71%) 8 ⁄ 16 (50%)
Tunneled CVC 10 ⁄ 89 (11%) 8 ⁄ 73 (11%) 2 ⁄ 16 (12.5%)
Peripheral intravenous line 6 ⁄ 89 (7%) 3 ⁄ 73 (4%) 3 ⁄ 16 (18%)
Central arterial catheter 3 ⁄ 89 (3%) 1 ⁄ 73 (1%) 2 ⁄ 16 (12.5%)
Peripheral arterial catheter 3 ⁄ 89 (3%) 3 ⁄ 73 (4%) 0 ⁄ 16 (0%)
Peripherally inserted CVC 2 ⁄ 89 (2%) 2 ⁄ 73 (3%) 0 ⁄ 16 (0%)
Antibiotic- or antiseptic-
impregnated CVC
2 ⁄ 89 (2%) 1 ⁄ 73 (1%) 1 ⁄ 16 (6.5%)
Other 3 ⁄ 89 (3%) 3 ⁄ 73 (4%) 0 ⁄ 16 (0%)
Multi-lumen catheter 60 ⁄ 84 (71%) 50 ⁄ 70 (71%) 10 ⁄ 14 (71%)
Parenteral nutrition given 46 ⁄ 86 (53.5%) 40 ⁄ 70 (57%) 6 ⁄ 16 (37.5%)
Type of skin antiseptic applied
Povidone iodine 54 ⁄ 89 (61%) 44 ⁄ 73 (60%) 10 ⁄ 16 (62.5%)
Chlorhexidine + alcohol 21 ⁄ 89 (24%) 17 ⁄ 73 (23%) 4 ⁄ 16 (25%)
Alcohol 8 ⁄ 89 (9%) 6 ⁄ 73 (8%) 2 ⁄ 16 (12.5%)
Chlorhexidine aqueous 4 ⁄ 89 (4.5%) 4 ⁄ 73 (5.5%) 0 ⁄ 16 (0%)
Other 2 ⁄ 89 (2%) 2 ⁄ 73 (3%) 0 ⁄ 89 (0%)
Catheter material
Polyurethane 54 ⁄ 74 (73%) 45 ⁄ 59 (76%) 9 ⁄ 15 (60%)
Silicone 7 ⁄ 74 (9%) 6 ⁄ 59 (10%) 1 ⁄ 15 (7%)
Teflon 5 ⁄ 74 (6.5%) 3 ⁄ 59 (5%) 2 ⁄ 15 (13%)
Polyvinyl chloride 5 ⁄ 74 (6.5%) 3 ⁄ 59 (5%) 2 ⁄ 15 (13%)
Antimicrobial-coated 3 ⁄ 74 (4%) 2 ⁄ 59 (3%) 1 ⁄ 15 (7%)
Catheter dressing
Sterile gauze 46 ⁄ 84 (55%) 36 ⁄ 69 (52%) 10 ⁄ 15 (67%)
Transparent dressing 36 ⁄ 84 (43%) 31 ⁄ 69 (45%) 5 ⁄ 15 (33%)
Others 2 ⁄ 84 (2.5%) 2 ⁄ 69 (3%) 0 ⁄ 15 (0%)
Practitioner inserting the catheter
Anaesthesist 50 ⁄ 89 (56%) 41 ⁄ 73 (56%) 9 ⁄ 16 (56%)
Surgeon 7 ⁄ 89 (8%) 5 ⁄ 73 (7%) 2 ⁄ 16 (12.5%)
Radiologist 2 ⁄ 89 (2%) 2 ⁄ 73 (3%) 0 ⁄ 16 (0%)
Other 30 ⁄ 89 (34%) 25 ⁄ 73 (34%) 5 ⁄ 16 (31%)
Grade of doctor
Junior 44 ⁄ 88 (50%) 35 ⁄ 73 (48%) 9 ⁄ 15 (60%)
Consultant 44 ⁄ 88 (50%) 38 ⁄ 73 (52%) 6 ⁄ 15 (40%)
IVC, intravenous catheter; CVC, central venous catheter.
Table 1. Characteristics of the hospitals supplying data for
the study
Total EU countries
Non-EU
countries
Population served 92 343 614 47 442 812 44 900 802
Number of beds
< 500 beds 34.6% 35.4% 32%
500–1000 beds 42.3% 45.6% 32%
> 1000 beds 23.1% 19% 36%
Admissions in the year 2000 4 549 757 2 444 076 2 105 681
CR-BSI episodes in the study perioda 89 73 16
CR-BSI ⁄ 1000 admissionsb 1.02 1.55 0.39
a22–26 October 2001.
bp < 0.0001.
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of unnecessary catheters could prevent most
episodes of CR-BSI. Total parenteral nutrition
was given to 40% of the patients in the present
study through multi-lumen catheters. This prac-
tice is not recommended by the UK Department of
Health [17], but the most recent USA guidelines
for the prevention of IVC infection did not
consider that specific situation [10].
In conclusion, this study shows clear room for
improvement in decisions concerning the choice,
indications, duration and care of IVCs, and offers
baseline data for the current situation in Europe.
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